Аннотация
Печеночная недостаточность (ПечН) различной этиологии характеризуется высокой летальностью, и единственным методом ее лечения по-прежнему остается трансплантация печени. Однако дефицит донорских органов может быть причиной гибели больных, находящихся в листе ожидания вследствие прогрессирования или острой декомпенсации ПечН, но так и не дождавшихся пересадки. Биологические системы экстракорпоральной поддержки печени потенциально могут оказать временную поддержку при ожидании донорского трансплантата. . В обзоре рассмотрены биологические системы экстракорпоральной поддержки печени и возможности биоинженерии, которые применяются для лечения больных с ПечН.
Литература
1. Graziadei I.W. The clinical challenges of acute on chronic liver failure // Liver International. – 2011. – V. 31. – P. 24–26. DOI: 10.1111/j.1478-3231.2011.02585.x.
2. Asrani S.K. et al. Burden of liver diseases in the world // Journal of hepatology. – 2019. – V. 70. – No 1. – P. 151–171. DOI: 10.1016/j.jhep.2018.09.014.
3. Devarbhavi H. et al. Global burden of liver disease: 2023 update // Journal of Hepatology. – 2023. – V. 79. – No 2. – P. 516–537. DOI: 10.1016/j.jhep.2023.03.017.
4. Kanjo A. et al. Efficacy and safety of liver support devices in acute and hyperacute liver failure: A systematic review and network meta-analysis // Scientific Reports. – 2021. – V. 11. – No 1. – P. 4189. DOI: 10.1038/s41598-021-83292-z.
5. García Martínez J.J. et al. Artificial liver support systems: what is new over the last decade? // Annals of intensive care. – 2018. – V. 8. – Р. 1–14. DOI: 10.1186/s13613-018-0453-z.
6. He Y.T. et al. Bioartificial liver support systems for acute liver failure: a systematic review and meta-analysis of the clinical and preclinical literature // World journal of gastroenterology. – 2019. – V. 25. – No 27. – P. 3634. DOI: 10.3748/wjg.v25.i27.3634.
7. Luo J. et al. Acute-on-chronic liver failure: far to go: a review // Critical Care. – 2023. – V. 27. – No 1. – P. 259. DOI: 10.1186/s13054-023-04540-4.
8. Кутепов Д.Е. и др. Возможности экстракорпоральных методов лечения печеночной недостаточности // Хирургия. Журнал им. Н.И. Пирогова. – 2014. – № 2. – С. 55–58. [Kutepov D.E. et al. Possibilities of extracorporeal methods of treatmentof liver failure // Surgery. Magazine named N.I. Pirogov – 2014. – No 2. – P. 55–58. In Russian].
9. Бояринцев В.В. и др. Хроническая печеночная недостаточность. – СПб: Фолиант, 2017. – С. 188. [Boyarintsev V.V. et al. Chronic liver failure. Saint-Petersburg: Foliant, 2017. – P. 188. In Russian].
10. Dominik A. et al. Similarities, differences, and potential synergies in the mechanism of action of albumin dialysis using the MARS albumin dialysis device and the Cytosorbhemoperfusion device in the treatment of liver failure // Blood purification. – 2021. – V. 50. – No 1. – P. 119–128. DOI: 10.1159/000508810.
11. Terrault N. A. et al. Liver transplantation 2023: status report, current and future challenges // Clinical Gastroenterology and Hepatology. – 2023. – V. 21. – No 8. – P. 2150–2166. DOI: 10.1016/j.cgh.2023.04.005.
12. Ghelichi-Ghojogh M. et al. Survival rate of liver transplantation in Asia: a systematic review and meta-analysis // Iranian Journal of Public Health. – 2022. – V. 51. – No 10. – P. 2207. DOI: 10.18502/ijph.v51i10.10979.
13. Готье С.В. и др. Донорство и трансплантация органов в Российской Федерации в 2015 году. VIII сообщение регистра Российского трансплантологического общества // Вестник трансплантологии и искусственных органов. – 2016. – Т. XVIII. – № 2. – С. 6–26. [Gautier S.V. et al. Organ donation and transplantation in Russian Federation in 2015. 8th report of National Register // Russian Journal of Transplantology and Artificial Organs. – 2016. – V. 18. – No 2. – P. 6–26. In Russian]. DOI: 10.15825/1995-1191-2016-2-6-26.
14. Kim W.R. et al. OPTN/SRTR 2013 annual data report: liver // American journal of transplantation. – 2015. – V. 15. – No S2. – P. 1–28. DOI: 10.1111/ajt.13197.
15. Kwong A. et al. OPTN/SRTR 2018 annual data report: liver // American Journal of Transplantation. – 2020. – V. 20. – P. 193–299. DOI: 10.1111/ajt.15674.
16. Wiesmann T. et al. Extracorporeal liver support: trending epidemiology and mortality-a nationwide database analysis 2007–2015 // BMC Gastroenterology. – 2019. – V. 19. – P. 1–10. DOI: 10.1186/s12876-019-1077-y.
17. Tandon R. et al. Artificial liver support systems // Journal of Gastroenterology and Hepatology. – 2021. – V. 36. – No 5. – P. 1164–1179. DOI: 10.1111/jgh.15255.
18. Van de Kerkhove M.P. et al. Clinical application of bioartificial liver support systems // Annals of surgery. – 2004. – V. 240. – No 2. – P. 216. DOI: 10.1097/01.sla.0000132986.75257.19.
19. Pitkin Z. et al. Evidence of absence of porcine endogenous retrovirus (PERV) infection in patients treated with a bioartificial liver support system // Artificial organs. – 1999. – V. 23. – No 9. – P. 829–833. DOI: 10.1046/j.1525-1594.1999.06444.x.
20. Di Nicuolo G. et al. Long‐term absence of porcine endogenous retrovirus infection in chronically immunosuppressed patients after treatment with the porcine cell–based Academic Medical Center bioartificial liver // Xenotransplantation. – 2010. – V. 17. – No 6. – P. 431–439. DOI: 10.1111/j.1399-3089.2010.00617.x.
21. Nguyen A. et al. Extracorporeal liver support: an updated review of mechanisms and current literature // Journal of Community Hospital Internal Medicine Perspectives. – 2022. – V. 12. – No 4. – P. 43. DOI: 10.55729/2000-9666.1064.
22. Thompson J. et al. Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: a multinational, prospective, controlled, randomized trial // Liver Transplantation. – 2018. – V. 24. – No 3. – P. 380–393. DOI: 10.1002/lt.24986.
23. Duan Z. et al. Comparison of extracorporeal cellular therapy (ELAD®) vs standard of care in a randomized controlled clinical trial in treating Chinese subjects with acute-on-chronic liver failure // Hepatic Medicine: Evidence and Research. – 2018. – P. 139–152. DOI: 10.2147/HMER.S180246.
24. Demetriou A.A. et al. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure // Annals of surgery. – 2004. – V. 239. – No 5. – P. 660. DOI: 10.1097/01.sla.0000124298.74199.e5.
25. Stutchfield B.M. et al. Systematic review and meta-analysis of survival following extracorporeal liver support // Journal of British Surgery. – 2011. – V. 98. – No 5. – P. 623–631. DOI: 10.1002/bjs.7418.
26. Van de Kerkhove M.P. et al. Liver support therapy: an overview of the AMC-bioartificial liver research // Digestive Surgery. – 2005. – V. 22. – No 4. – P. 254–264. DOI: 10.1159/000088055.
27. Mazariegos G.V. et al. Safety observations in phase I clinical evaluation of the Excorp Medical Bioartificial Liver Support System after the first four patients // Asaio Journal. – 2001. – V. 47. – No 5. – P. 471–475. DOI: 10.1097/00002480-200109000-00015.
28. Mazariegos G.V. et al. First clinical use of a novel bioartificial liver support system (BLSS) // American Journal of Transplantation. – 2002. – V. 2. – No 3. – P. 260–266. DOI: 10.1034/j.1600-6143.2002.20311.x.
29. Sauer I.M. et al. Primary human liver cells as source for modular extracorporeal liver support-a preliminary report // The International Journal of Artificial Organs. – 2002. – V. 25. – No 10. – P. 1001–1005. DOI: 10.1177/039139880202501015.
30. Morsiani E. et al. Early experiences with a porcine hepatocyte-based bioartificial liver in acute hepatic failure patients // The International Journal of Artificial Organs. – 2002. – V. 25. – No 3. – P. 192–202. DOI: 10.1177/039139880202500305.
31. Xue Y.L. et al. TECA hybrid artificial liver support system in treatment of acute liver failure // World Journal of Gastroenterology. – 2001. – V. 7. – No 6. – P. 826. DOI: 10.3748/wjg.v7.i6.826.
32. Ding Y.T. et al. The development of a new bioartificial liver and its application in 12 acute liver failure patients // World Journal of Gastroenterology: WJG. – 2003. – V. 9. – No 4. – P. 829. DOI: 10.3748/wjg.v9.i4.829.
33. Cardinale V. et al. Cell transplantation-based regenerative medicine in liver diseases // Stem Cell Reports. – 2023. – V. 18. – No 8. – P. 1555–1572. DOI: 10.1016/j.stemcr.2023.06.005.
34. Nevens F. et al. A phase II study of human allogeneic liver-derived progenitor cell therapy for acute-on-chronic liver failure and acute decompensation // Jhep Reports. – 2021. – V. 3. – No 4. – P. 100291. DOI: 10.1016/j.jhepr.2021.100291.